First FDA Approval Establishes New Medical Device Category

On August 19, 2026, Vitestro B.V., a Dutch medical robotics company, received FDA De Novo marketing authorization for its Aletta, the first autonomous robot in the U.S. to draw venous blood from adult arms without direct manual operation by healthcare professionals. The De Novo pathway is applied to low- to moderate-risk novel devices lacking comparable predicates, and the FDA also set specific controls for labeling, performance, and clinical trials. As a result, follow-on products may seek 510(k) equivalence based on the regulatory framework established by Aletta, extending the first-mover advantage beyond technology to regulatory assets.

ADOPT Multicenter Trial Validates Performance and Safety

The clinical basis for approval, the prospective multicenter ADOPT trial (NCT05878483), evaluated 1,633 patients across three outpatient phlebotomy centers in the Netherlands and collected patient acceptance data from the Mayo Clinic in the U.S. The first-attempt success rate was 94.5% in patients with suitable veins, with 97.4% in those with a BMI over 30, 92.7% in self-reported difficult venous access, and 93.4% in those over 65 years old. Hemolysis rate was 0.3%, and device-related adverse events were 0.6%, all mild, thereby reducing concerns about automated systems compromising sample quality. However, the denominator for success rate includes only patients in whom the device identified suitable veins and proceeded with the puncture, which should be considered when evaluating actual throughput and manual conversion rates.

Integrated Imaging and Robotics Automate Entire Blood Draw Process

Aletta combines near-infrared (NIR), ultrasound, and Doppler ultrasound to 3D map veins, distinguish between arteries and veins, and insert the needle via a robotic arm. It automatically performs tourniquet application, skin preparation, tube replacement and mixing, needle disposal, and bandage application. If excessive patient movement is detected, the device disengages the needle and halts the procedure. While a single trained phlebotomist can supervise up to three units, session initiation, tube sequence and charge status checks, and device cleaning between patients require trained personnel. Rather than fully replacing manual venipuncture by skilled staff, Aletta is designed to parallelize repetitive outpatient phlebotomy, reducing staffing bottlenecks and variability between operators.

Commercialization in Europe and U.S. Expansion Funded

Aletta received CE marking under the EU Medical Device Regulation (MDR) in August 2024 and has been commercialized in Europe. The FDA approval now provides a foundation for entry into the world's largest medical device market. Vitestro closed a $70 million Series B round in March 2026, led by Labcorp Ventures, Mayo Clinic, and Sutter Health, to scale manufacturing and build commercial infrastructure. Competitors include France's BHealthCare with HEIVA and U.S.-based Veebot Systems with its image-guided robotic needle insertion platform. However, Aletta's key differentiator is being the only commercially available product with both FDA and CE approvals. As the global blood draw device market is projected to reach $10.1 billion in 2026, early adoption will depend more on throughput, manual conversion frequency, hospital information system integration, and service uptime than on equipment price.